BridgeBio Pharma (BBIO) Non-Current Debt (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Non-Current Debt data on file, last reported at $2.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt changed N/A year-over-year to $2.7 billion; the trailing twelve-month figure through Mar 2026 stood at $2.7 billion (changed N/A YoY), and the FY2025 full-year result was $740.9 million, up 69.41% from the prior year.
• Non-Current Debt advanced to $2.7 billion in Q1 2026, from $740.9 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $2.7 billion in Q1 2026 to a low of $418.4 million in Q2 2022.
• A 5-year average of $707.7 million and a median of $436.2 million in 2024 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt surged 378.3% in 2022 and dropped 2.04% in 2024, its largest moves.
• Tracing BBIO's Non-Current Debt over 5 years: stood at $431.0 million in 2022, then rose by 3.59% to $446.4 million in 2023, then retreated by 2.04% to $437.3 million in 2024, then surged by 69.41% to $740.9 million in 2025, then soared by 258.07% to $2.7 billion in 2026.
• Business Quant data shows BBIO's Non-Current Debt at $2.7 billion in Q1 2026, $740.9 million in Q4 2025, and $2.0 billion in Q3 2025.